Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...
Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui as its Chair Designate. Dr. Slaoui, a notable figure ...
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
Oil and gas companies Arcturus Corp. and Aschere Energy LLC, along with founder Leon Ali Parvizian, must pay more than $10 ...
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...
In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...
The co-development and project finance agreement will accelerate deployment of Skyven's cutting-edge, "decarbonizing" ...
公司总裁兼首席执行官Joseph Payne对Slaoui博士的新任命表示热切期待，认为这将是Arcturus治疗和疫苗开发项目的重要一年。Slaoui博士本人也对这一时期的转型潜力发表评论，预计公司的研发管线将产生多个重要数据。 InvestingPro 分析表明，该股票目前被低估，但投资者应注意分析师预计今年净收入将下降。
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
周一，H.C. Wainwright对Arcturus Therapeutics股票保持积极态度，重申买入评级，目标价为63美元。根据 InvestingPro 数据，该股目前交易价为16.97美元，分析师目标价区间为41美元至140美元，显示出巨大的上涨潜力。该公司的认可紧随明治制药（Meiji Seika ...
Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback